BEGIN:VCALENDAR VERSION:2.0 PRODID:-//PsychU - ECPv6.1.4//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:PsychU X-ORIGINAL-URL:https://psychu.org X-WR-CALDESC:Events for PsychU REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:America/New_York BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20220313T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20221106T060000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20230312T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20231105T060000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20240310T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20241103T060000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=America/New_York:20240228T120000 DTEND;TZID=America/New_York:20240228T123000 DTSTAMP:20240328T044025 CREATED:20240103T183318Z LAST-MODIFIED:20240228T174807Z UID:10004008-1709121600-1709123400@psychu.org SUMMARY:Exploring Post-Traumatic Stress Disorder: Treatment Landscape & Unmet Needs DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n Current evidence-based guidelines for the diagnosis and treatment of post-traumatic stress disorder (PTSD) are valuable resources and can be used to help develop individual treatment plans for patients. This webinar will examine the current PTSD treatment landscape\, including discussions on both psychotherapy and pharmacotherapy. In addition\, presenters will review limitations and key considerations in the treatment of PTSD. \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n David Block\, MD\, MMM\, FAPA\n Clinical Assistant Professor of Psychiatry\, Western University of Health Sciences\, Loma Linda University and California University of Health and Medicine; Private Practitioner\, Costa Mesa\, CA \n \n \n More\n \n Dr. David Block\, a psychiatrist in Orange County\, CA\, is dual board-certified in psychiatry and addiction medicine and was elected to become a Fellow of the American Psychiatric Association in January 2014. Currently\, he is the Clinical Assistant Professor of Psychiatry at the Western University of Health Sciences\, Loma Linda University and California University of Health and Medicine\, and is a Private Practitioner in Costa Mesa\, CA.\n\nDr. Block has worked extensively in college mental health\, managed health care\, and community treatment settings with severely and persistently mentally ill individuals. He has extensive clinical experience working with individuals with PTSD\, from both his public and private sector work\, Additionally\, he has written several articles in the psychiatric literature and taught seminars and lectures to students training in the mental health professions. \n\n \n \n\n\n \n \n \n \n Madeline Shurtleff\, PharmD (OPDC)\n Managed Market Liaison \n \n \n More\n \n Dr. Shurtleff is a clinical pharmacist with experience in managed care and retail pharmacy. She has extensive knowledge in Medicaid and Medicare pharmacy operations and regulatory requirements. Dr. Shurtleff received her Doctor of Pharmacy (PharmD)\, Business Minor\, and Leadership Minor from the University of Rhode Island. She is a licensed pharmacist in Illinois and Arizona.\n \n \n\n\nDavid Block\, MD\, MMM\, FAPA is a paid consultant of Otsuka Pharmaceutical Development & Commercialization\, Inc.Madeline Shurtleff\, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. URL:https://psychu.org/event/exploring-post-traumatic-stress-disorder-treatment-landscape-unmet-needs/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2024/01/Shutterstock_2387841697.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20240222T120000 DTEND;TZID=America/New_York:20240222T130000 DTSTAMP:20240328T044025 CREATED:20240123T152031Z LAST-MODIFIED:20240222T164957Z UID:10004018-1708603200-1708606800@psychu.org SUMMARY:Let’s Face It\, The Current Treatment Options For MDD Are Not Enough: Learn About Cognitive Emotional Training DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n During an expert interview\, Otsuka Sr. MSL\, Dr. Mark Tacelosky will be talking with Dr. Brian Iacoviello who will guide us through Cognitive Emotional Training for the treatment of major depressive disorder (MDD). The objectives of this activity include providing the rationale for the role of cognitive-emotional training\, exploring the steps for developing a cognitive-emotional training intervention for the treatment of MDD\, reviewing the options for the digital delivery of cognitive emotional training\, and discussing the possibilities for future research and applications. \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Brian Iacoviello\, PhD\n Assistant Professor\, Icahn School of Medicine at Mount Sinai New York\, NY\n \n \n \n More\n \n Dr. Iacoviello is a clinical psychologist and assistant professor at the Icahn School of Medicine at Mount Sinai. He earned his Masters and PhD in clinical psychology from Temple University in PA. Dr Iacoviello specializes in treating mood and anxiety disorders\, using cognitive behavioral therapy\, dialectical behavior therapy\, acceptance and commitment therapy and motivational interviewing. His research delves into understanding fundamental cognitive behavioral patterns associated with depression\, bipolar disorder\, and anxiety disorders to search for novel treatments\n \n \n\n\n \n \n \n \n Mark Tacelosky\, PharmD (OPDC)\n Senior Medical Science Liaison \n \n \n \n\n\nBrian Iacoviello\, PhD is a paid consultant for Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)Mark Tacelosky\, PharmD is an employee for Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. URL:https://psychu.org/event/lets-face-it-the-current-treatment-options-for-mdd-are-not-enough-learn-about-cognitive-emotional-training/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2024/01/Shutterstock_2410022633.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20231213T150000 DTEND;TZID=America/New_York:20231213T160000 DTSTAMP:20240328T044025 CREATED:20231107T162058Z LAST-MODIFIED:20231213T222722Z UID:10004001-1702479600-1702483200@psychu.org SUMMARY:Conversations Matter: The Importance Of Effective Communication Between Healthcare Providers & Care Partners Of Individuals Living With Agitation In Alzheimer’s Dementia (AAD) DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n Care partners play an integral role in the detection and assessment of agitation symptoms in patients with Alzheimer’s dementia1 and are often the first to communicate these behaviors to healthcare providers (HCPs)2\,3. Early identification\, management and treatment of AAD has been shown to improve patient outcomes and reduce caregiver burden4\,5\, highlighting the importance of a strong therapeutic alliance between care partners and HCPs. In this webinar\, geriatric psychiatrist\, Dr. Marc Agronin\, and care partner\, Carrie Shaw\, share their unique but complimentary perspectives on identifying and responding to agitation and navigating the shared decision-making process. Our speakers will discuss best practices for how to effectively prepare for and communicate during an appointment and what tools and resources are available for care partners. One such tool they review is the AASC™\, a brief screening tool based on the International Psychogeriatric Association (IPA) consensus definition for agitation in cognitive disorders6\, which was designed to assist caregivers in recognizing AAD.\n\n\nClick here to register for the 12:00 pm EST broadcast\n\n\nReferences:\n\n Stella F\, et al. Int J Geriatr Psychiatry. 2015;30(12):1230-1237\n Lindeza P\, et al. BMJ Support Palliat Care. 2020; bmjspcare-2020-002242.\n Gallego-Alberto L\, et al. Clin Gerontol. 2022;45(5):1295-1303.\n Hoe J\, et al. BJPsych Open. 2017;3(1):34-40.\n Janzen S\, et al. Am J Alzheimers Dis Other Demen. 2013;28(5):524-532\n Sano M\, et al. International Psychogeriatrics 2023 :1-13. doi10.1017/S1041610222001041\n \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Marc E. Agronin\, MD\n Agitation Section Advisor; President of the American Association for Geriatric Psychiatry (AAGP); Senior Vice President for Behavioral Health and Chief Medical Office for the Memory and Research Center at MIND Institute; Affiliate Associate Professor of Psychiatry and Neurology at the University of Miami Miller School of Medicine \n \n \n \n\n\n \n \n \n \n Carrie Shaw\, MD\n CEO & Founder of Embodied Labs \n \n \n \n\n\n \n \n \n \n Miranda Fisher\, PhD (OPDC)\n Medical Science Liaison \n \n \n \n\n\n\n\n\n\nMarc Agronin and Carrie Shaw are paid consultants of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)Miranda Fisher\, PhD is a paid employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. URL:https://psychu.org/event/conversations-matter-the-importance-of-effective-communication-between-healthcare-providers-care-partners-of-individuals-living-with-agitation-in-alzheimers-dementia-aad-3pm/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/11/Son-and-Elderly-Father_Conversation_Alzheimers_912x506_shutterstock_2070560411.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20231213T120000 DTEND;TZID=America/New_York:20231213T130000 DTSTAMP:20240328T044025 CREATED:20231107T162104Z LAST-MODIFIED:20231213T210333Z UID:10004002-1702468800-1702472400@psychu.org SUMMARY:Conversations Matter: The Importance Of Effective Communication Between Healthcare Providers & Care Partners Of Individuals Living With Agitation In Alzheimer's Dementia (AAD) DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n Care partners play an integral role in the detection and assessment of agitation symptoms in patients with Alzheimer’s dementia1 and are often the first to communicate these behaviors to healthcare providers (HCPs)2\,3. Early identification\, management and treatment of AAD has been shown to improve patient outcomes and reduce caregiver burden4\,5\, highlighting the importance of a strong therapeutic alliance between care partners and HCPs. In this webinar\, geriatric psychiatrist\, Dr. Marc Agronin\, and care partner\, Carrie Shaw\, share their unique but complimentary perspectives on identifying and responding to agitation and navigating the shared decision-making process. Our speakers will discuss best practices for how to effectively prepare for and communicate during an appointment and what tools and resources are available for care partners. One such tool they review is the AASC™\, a brief screening tool based on the International Psychogeriatric Association (IPA) consensus definition for agitation in cognitive disorders6\, which was designed to assist caregivers in recognizing AAD.\n\n\nClick here to register for the 3:00 pm EST broadcast\n\n\nReferences:\n\n Stella F\, et al. Int J Geriatr Psychiatry. 2015;30(12):1230-1237\n Lindeza P\, et al. BMJ Support Palliat Care. 2020; bmjspcare-2020-002242.\n Gallego-Alberto L\, et al. Clin Gerontol. 2022;45(5):1295-1303.\n Hoe J\, et al. BJPsych Open. 2017;3(1):34-40.\n Janzen S\, et al. Am J Alzheimers Dis Other Demen. 2013;28(5):524-532\n Sano M\, et al. International Psychogeriatrics 2023 :1-13. doi10.1017/S1041610222001041\n \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Marc E. Agronin\, MD\n Agitation Section Advisor; President of the American Association for Geriatric Psychiatry (AAGP); Senior Vice President for Behavioral Health and Chief Medical Office for the Memory and Research Center at MIND Institute; Affiliate Associate Professor of Psychiatry and Neurology at the University of Miami Miller School of Medicine \n \n \n \n\n\n \n \n \n \n Carrie Shaw\, MD\n CEO & Founder of Embodied Labs \n \n \n \n\n\n \n \n \n \n Miranda Fisher\, PhD (OPDC)\n Medical Science Liaison \n \n \n \n\n\n\n\n\n\nMarc Agronin and Carrie Shaw are paid consultants of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) Miranda Fisher\, PhD is a paid employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. URL:https://psychu.org/event/conversations-matter-the-importance-of-effective-communication-between-healthcare-providers-care-partners-of-individuals-living-with-agitation-in-alzheimers-dementia-aad-12pm/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/11/Son-and-Elderly-Father_Conversation_Alzheimers_912x506_shutterstock_2070560411.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20231129T120000 DTEND;TZID=America/New_York:20231129T130000 DTSTAMP:20240328T044025 CREATED:20231030T203117Z LAST-MODIFIED:20231129T164726Z UID:10003999-1701259200-1701262800@psychu.org SUMMARY:The Agitation In Alzheimer's Screener For Caregivers (AASC™) - A New Tool To Disease Recognition DESCRIPTION:Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n Agitation is one of the most common neuropsychiatric symptoms of Alzheimer’s dementia\, and one of the most complex\, prominent\, stressful\, and costly aspects of care.1 Caregivers are often first to encounter agitation-associated behaviors and play a pivotal role in communicating these symptoms to healthcare providers (HCPs).2\,3 Agitation associated with Alzheimer’s dementia (AAD) causes a significant clinical\, humanistic\, and economic burden on community\, family\, and professional caregivers.4\,5\,6\,7 AAD is notably underdiagnosed\, and most caregivers do not identify the breadth of signs/symptoms of agitation and are hesitant to discuss these behaviors with HCPs.8 Therefore\, there’s a need for an easy\, pragmatic screener to facilitate caregiver recognition of AAD and HCP discussions. AASC™\, a brief screening tool based on the International Psychogeriatric Association (IPA) consensus definition for agitation in cognitive disorders\,9 was designed to assist caregivers in recognizing AAD. Dr. Carolyn Clevenger will discuss development of the AASC™ tool and its potential to improve communication between caregivers and providers\, and ultimately recognition of agitation behaviors.\nReferences: \n\n\n Halpern R\, et al. Int J Geriatr Psychiatry. 2019;34(3):420-431\n Lindeza P\, et al. BMJ Support Palliat Care. 2020; bmjspcare-2020-002242\n Gallego-Alberto L\, et al. Clin Gerontol. 2022;45(5):1295-1303\n Fillit H\, et al. Int J Geriatr Psychiatry. 2021 ;36(12) :1959-1969\n Jones E\, et al. J Alzheimers Dis. 2021 ;83(1) :89-101\n Schein J\, et al. J Alzheimers Dis. 2022 ;88(2) :663-677\n Palm R\, et al. J Alzheimers Dis. 2018 ;66(4) :1463-1470\n Lanctot KL\, et al. Alzheimers Dement (NY). 2017 ;3(3) :440-449\n Sano M\, et al. International Psychogeriatrics 2023 :1-13. doi10.1017/S1041610222001041\n \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Carolyn Clevenger\, DNP\, RN\, GNP-BC\, AGPCNP-BC\, FAANP\, FGSA\n Professor of Transformative Clinical Practice\, Emory University School of Nursing\, Clinical Director and Gerontological Nurse Practitioner at Integrated Memory Care Clinic \n \n \n More\n \n Carolyn Clevenger DNP\, RN\, GNP-BC\, AGPCNP-BC\, FAANP\, FGSA\, is Professor of Transformative Clinical Practice at the Emory University School of Nursing in Atlanta\, Georgia. She serves as Clinical Director and Gerontological Nurse Practitioner at Emory’s Integrated Memory Care Clinic\, a patient-centered medical home providing integrated memory care and primary care for persons living with dementia. She is a Past President of the Gerontological Advanced Practice Nurses Association\, and Fellow of the American Association of Nurse Practitioners (AANP) and the Gerontological Society of America.\n \n \n\n\n \n \n \n \n Mike Crooks\, PharmD\, BCGP (OPDC)\n Senior Long-Term Care Medical Science Liaison \n \n \n \n\n\nSpeaker Carolyn Clevenger DNP\, RN\, GNP-BC\, AGPCNP-BC\, FAANP\, FGSA is a paid consultant for Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)Moderator Mike Crooks\, Pharm D\, BCGP is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. \n \n \n \n \n \n \n\n\n\n\n \n \n \n Home\n \n \n \n \n Events\n \n \n \n \n Webinar URL:https://psychu.org/event/the-agitation-in-alzheimers-screener-for-caregivers-aasc-a-new-tool-to-disease-recognition/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/10/Assessment-Tool_Agitation-in-Alzheimers_912x506_shutterstock_716614579.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20231115T120000 DTEND;TZID=America/New_York:20231115T130000 DTSTAMP:20240328T044025 CREATED:20231019T151436Z LAST-MODIFIED:20240116T172341Z UID:10003997-1700049600-1700053200@psychu.org SUMMARY:Exploring Post-Traumatic Stress Disorder: Disease Burden DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n Post-traumatic stress disorder (PTSD) has a high impact on quality of life\, which can negatively affect patient outcomes and relationships with others. These patients also have an increased risk of medical comorbidities and mortality\, increasing the burden on the healthcare system and society. This virtual event will further examine the patient\, humanistic\, clinical\, and economic burden of PTSD. \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n David Purselle\, MD\, MSCR\n Board-certified psychiatrist with over 20 years of clinical experience\, Director of Georgia Psychiatric Consultants and an adjunct faculty member at Morehouse School of Medicine \n \n \n More\n \n Dr. David Purselle is a board-certified psychiatrist with over 20 years of clinical experience working in a variety of settings\, including outpatient clinics\, emergency rooms\, and inpatient units at the Atlanta VA Medical Center\, Emory University Hospital\, and Grady Hospital. Currently\, he is the Director of Georgia Psychiatric Consultants and an adjunct faculty member at Morehouse School of Medicine. He is also involved with several clinical research studies studying the effectiveness of various antidepressants\, mood stabilizers\, antipsychotics\, and lithium.\n\n\nDr. Purselle has been recognized as a physician leader in several forums and presented continuing medical education programs at national and local conferences. He has also served as a consultant for major pharmaceutical corporations providing guidance on development of new therapies for a variety of mental illnesses.\n \n \n\n\n \n \n \n \n Erika Modh\, PharmD\, BCPS (OPDC)\n Medical Science Liaison \n \n \n \n\n\n\n\n\n\nDavid Purselle is a paid consultant of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) Erika Modh is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. URL:https://psychu.org/event/exploring-post-traumatic-stress-disorder-disease-burden/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/10/PTSD_912x506_shutterstock_1977078593.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20231109T120000 DTEND;TZID=America/New_York:20231109T130000 DTSTAMP:20240328T044025 CREATED:20231019T151157Z LAST-MODIFIED:20231109T211454Z UID:10003996-1699531200-1699534800@psychu.org SUMMARY:Walking The Tight Rope: A Discussion Of Striking The Right Balance In Depression\, With A Focus On Norepinephrine DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n Join us for a PsychU webinar with Drs. Vladimir Maletic\, Craig Chepke\, and Jason Carter as they discuss the potential role of norepinephrine in Major Depressive Disorder\, as part of the monoaminergic theory of depression. \n\nDespite the efficacy of first-line anti-depressant treatments in MDD\, many individuals continue to experience unresolved symptoms that may impair their daily functioning and increase the healthcare burden. In fact\, the STAR*D study demonstrated approximately one third of patients with MDD achieved remission following treatment with first-line antidepressants\, highlighting the need to address unresolved and persistent symptoms of depression.1 Recent studies have shown that norepinephrine\, a neurotransmitter which regulates concentration\, energy levels\, and arousal\, may play a crucial role in the persistence of depression symptoms.2 \n\nOur webinar aims to provide valuable insights into the complex nature of depression and the potential role of norepinephrine in the pathophysiology of depression. \n\n \n\nReferences:\n\n Rush AJ et al. Am J Psychiatry. 2006;163:1905-1917\n Maletic V\, et al. Front Psychiatry. 2017;8:42.\n \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Vladimir Maletic\, MD\n Serves as Clinical Professor\, Psychiatry/Behavioral Science\, University of South Carolina School of Medicine Greenville\, SC \n \n \n More\n \n Vladimir Maletic\, MD serves as Clinical Professor\, Psychiatry/Behavioral Science\, School of Medicine Greenville\, SC and has been rated as Best Doctors of the America Registry and Psychiatrist of the year. Dr. Maletic received the Upjohn Achievement Award and Student Council teaching award and faculty award for teaching achievement. He also has received the Medical School Award for Academic Achievement.\n \n \n\n\n \n \n \n \n Craig Chepke\, MD\, FAPA\n Board-Certified Psychiatrist\, Fellow of the American Psychiatric Association\, Private practice at Excel Psychiatric Associates in Huntersville\, NC\, Adjunct Associate Professor of Psychiatry for Atrium Health and University of North Carolina School of Medicine \n \n \n More\n \n Excel Psychiatric Associates\, Atrium Health\, and University of North Carolina School of Medicine Dr. Chepke is a Board-Certified psychiatrist and a Fellow of the American Psychiatric Association. He has a private practice at Excel Psychiatric Associates in Huntersville\, NC and serves as an Adjunct Associate Professor of Psychiatry for Atrium Health and an Adjunct Assistant Professor of Psychiatry for the University of North Carolina School of Medicine. He has special interests in treatment-resistant and severe mental illness\, movement disorders\, ADHD\, and sleep medicine. Dr. Chepke is a member of the Huntington Study Group and serves on the board of directors for the CURESZ foundation\, a nonprofit organization dedicated to improving the lives of people living with Schizophrenia\n \n \n\n\n \n \n \n \n Jason Carter\, PharmD (OPDC)\n Senior Medical Science Liaison\, Neuroscience Field Medical Affairs \n \n \n \n\n\n\n\n\n\nVladimir Maletic and Craig Chepke are paid consultants of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)Jason Carter is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. URL:https://psychu.org/event/walking-the-tight-rope-a-discussion-of-striking-the-right-balance-in-depression-with-a-focus-on-norepinephrine/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/10/Depression_Psychiatrist_patient_912x506_shutterstock_2093817313.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20231016T120000 DTEND;TZID=America/New_York:20231016T130000 DTSTAMP:20240328T044025 CREATED:20230913T200130Z LAST-MODIFIED:20240220T205130Z UID:10003989-1697457600-1697461200@psychu.org SUMMARY:Exploring Post-Traumatic Stress Disorder: Trauma\, Trends & Diagnostic Insights DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n The global effects of trauma\, both physiologically and psychologically on individuals\, are extensive. This webinar will examine the prevalence of post-traumatic stress disorder (PTSD)\, explore trauma types\, review important screening and diagnostic tools\, and delve into the complexities encountered during the initial presentation and subsequent assessment PTSD. \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Saundra Jain\, MA\, PsyD\, LPC\n Adjunct Clinical Affiliate for the School of Nursing at the University of Texas\, Austin; Co-founder of WILD-5 Wellness® \n \n \n More\n \n Saundra Jain is an Adjunct Clinical Affiliate for the School of Nursing at The University of Texas\, Austin\, Texas. She is very focused on wellness and the impact of positive psychology on client outcomes. She launched a private practice of psychotherapy where she currently provides services for a wide range of mental health issues.\n\n\nDr. Jain is a co-creator of the WILD 5 Wellness Program\, which combines five elements of wellness (exercise\, mindfulness\, sleep\, social connectedness\, and nutrition) into a prescriptive\, easy-to-follow wellness program. She is very active in the area of peer-to-peer education\, especially in the disease states of depression\, bipolar disorder\, anxiety disorders\, and ADHD. She is the co-creator and co-presenter of a novel interactive workshop addressing the challenges of dealing with psychiatric co-morbidities through the use of psychiatric scales and screeners. She also serves as a member of the Psych Congress Committee providing direction regarding educational gaps & needs for healthcare practitioners in the world of mental health.\n\n\nCo-founder WILD-5 Wellness®\n \n \n\n\n \n \n \n \n Elika Hefazi\, PharmD\, BCPP (OPDC)\n Medical Science Liaison \n \n \n \n\n\nSaundra Jain is a paid consultant of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)Elika Hefazi is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. URL:https://psychu.org/event/exploring-post-traumatic-stress-disorder-trauma-trends-diagnostic-insights/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/09/shutterstock_2180809683-e1696468373203.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20231011T120000 DTEND;TZID=America/New_York:20231011T130000 DTSTAMP:20240328T044025 CREATED:20230623T174515Z LAST-MODIFIED:20231011T203042Z UID:10003974-1697025600-1697029200@psychu.org SUMMARY:The Impact Of Adherence In Patients With Bipolar I Disorder DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n Treatment non-adherence is a dilemma in bipolar disorder and is one of the leading challenges in providing effective treatments for people diagnosed with BP I disorder. During our discussion\, Dr. Sajatovic and Dr. Goldberg will discuss and define some of these challenges and provide the latest information on treatment-related determinants of adherence. They will also discuss some of the factors important to adherence. \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Martha Sajatovic\, MD\n Psychiatrist\, Director Neurological and Behavioral Outcomes Center\, University Hospital Cleveland Medical Center and Professor\, Case Western Reserve University School of Medicine \n \n \n More\n \n Martha Sajatovic\, MD holds the Willard Brown Chair in Neurological Outcomes at University Hospitals Cleveland Medical Center (UH CMC) and the Rocco L. Motto Professorship in Child & Adolescent Psychiatry. Dr. Sajatovic directs the Neurological and Behavioral Outcomes Center at UHCMC/Case Western Reserve University. She has subspecialty certification in Behavioral Neurology & Neuropsychiatry. Dr. Sajatovic is a Professor of Psychiatry and Neurology at Case Western Reserve University School of Medicine (CWRU) in Cleveland\, Ohio. Dr. Sajatovic is a researcher\, educator\, and clinician who has devoted herself to studying and treating traditionally\, hard-to-treat populations with central nervous system disorders. Dr. Sajatovic’s research interests have focused on neuropsychiatric outcomes of brain disorders across the life-span\, including epilepsy\, stroke\, Alzheimer’s disease\, and other types of dementia and Parkinson’s disease. She has authored or co-authored over 250 peer-reviewed publications and has published over 40 book chapters or books on neuropsychiatric topics. Dr. Sajatovic has been a recipient of the Exemplary Psychiatrist Award bestowed by the National Alliance for the Mentally Ill (NAMI)\, was a Depression and Bipolar Support Alliance (DBSA) Gerald Klerman Investigator Award winner in 2006 and 2016\, and in 2018 received the Rebecca Goldberg Kaufman American Epilepsy Society (AES) Clinical Award in Ethical Neuropsychiatry.\n \n \n\n\n \n \n \n \n Joseph Goldberg\, MD\n Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai\n \n \n \n More\n \n Dr. Goldberg currently serves as the Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai and serves on the Board of Directors for the American Society of Clinical Psychopharmacology. Dr. Goldberg has published over 200 peer-reviewed papers on topics related to the treatment and clinical features of bipolar disorder\, as well as three books on bipolar disorder and psychopharmacology.\n \n \n\n\n \n \n \n \n Elizabeth DiNapoli\, PhD (OPDC)\n Senior Medical Science Liaison \n \n \n More\n \n Dr. DiNapoli earned her PhD from the University of Alabama.\n \n \n\n\nSpeakers Martha Sajatovic\, MD and Joseph Goldberg\, MD are paid consultants for Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)Speaker Elizabeth DiNapoli\, PhD is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. URL:https://psychu.org/event/the-impact-of-adherence-in-patients-with-bipolar-i-disorder/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/06/Shutterstock_1918015181.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20231005T120000 DTEND;TZID=America/New_York:20231005T130000 DTSTAMP:20240328T044025 CREATED:20230919T202927Z LAST-MODIFIED:20231006T200134Z UID:10003981-1696507200-1696510800@psychu.org SUMMARY:Behavioral Health Quality Trends Affecting Payers DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n The evolving trends of mental healthcare quality measures have a marked impact on payers. Join Molly Burich and Madeline Shurtleff in this discussion that will review current behavioral health quality measures\, social determinations of health\, and the outcome each has on payers. \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Molly Burich\, (OPDC)\n Senior Director\, Reimbursement & Health Policy\, Government Affairs\, Otsuka America Pharmaceutical\, Inc. \n \n \n \n\n\n \n \n \n \n Madeline Shurtleff\, PharmD (OPDC)\n Managed Market Liaison \n \n \n More\n \n Dr. Shurtleff is a clinical pharmacist with experience in managed care and retail pharmacy. She has extensive knowledge in Medicaid and Medicare pharmacy operations and regulatory requirements. Dr. Shurtleff received her Doctor of Pharmacy (PharmD)\, Business Minor\, and Leadership Minor from the University of Rhode Island. She is a licensed pharmacist in Illinois and Arizona.\n \n \n\n\nMolly Burich & Madeline Shurtleff are employees of Otsuka American Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. URL:https://psychu.org/event/behavioral-health-quality-trends-affecting-payers/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/09/Quality-Trends-Affecting-Payers_912x506_shutterstock_1029998605-e1698951603907.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20230927T120000 DTEND;TZID=America/New_York:20230927T130000 DTSTAMP:20240328T044025 CREATED:20230804T204626Z LAST-MODIFIED:20230927T203404Z UID:10003383-1695816000-1695819600@psychu.org SUMMARY:Suicide Awareness & Prevention: PsychU Resource Review & Discussion DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n The PsychU community is cordially invited to join Drs. Amica Simmons-Yon and Rachel Self as they discuss the critically important topic of suicide awareness and prevention. An overview of resources available on PsychU as well as some of the leading national organizations devoted to suicide awareness and prevention will be provided. Appropriate language\, ongoing initiatives\, screening tools\, and navigation through materials on PsychU will also be highlighted. We all have a role to play in increasing suicide awareness\, providing support\, and directing individuals in need to potentially life-saving resources. Join us for this opportunity to learn and grow as we all strive to improve our mental health… together! \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Amica Simmons-Yon\, PharmD\, PhD (OPDC)\n Senior Medical Science Liaison\, Neuroscience Field Medical Affairs \n \n \n \n\n\n \n \n \n \n Rachel Self\, PhD\, MS (OPDC)\n Medical Science Director\, Neuroscience Field Medical Affairs \n \n \n More\n \n \n\nRachel Self\, PhD\, MS is a Medical Science Director for Otsuka’s Neuroscience Field Medical Affairs\, neuroscientist\, & wellness advocate\n\n\n \n \n\n\nAmica Simmons-Yon and Rachel Self are employees of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\nIf you or someone you know is in crisis\,call 988 or the Suicide Prevention Hotline/Lifeline 1-800-273-TALK(8255)or text the Crisis Text Line 741-741 \n\n\n\n\n\n\n\n \n Related Resources\n \n \n\n\n\n\n\n\nPsychU Suicide Awareness Resources:Suicide Awareness – PsychU \n\n\n\nPsychU 988 Webinar:988: What’s The Scoop? A Discussion With Experts In Suicide Prevention & Mental Health – PsychU \n\n\n\nSuicide Prevention Resource Center:https://sprc.org/ \n\n\n\nAmerican Foundation for Suicide Prevention: Become an Advocate:Advocate for suicide prevention | AFSP \n\n\n\nPsychU Interview on Stahl’s Clinical Handbook Suicide Prevention Edition:Stahl’s Handbook Suicide Prevention Edition: An Interview With Drs. Christine Moutier & Anthony Pisani – PsychU \n\n\n\n988 Update Analysis:One Year After the Launch of 988\, the National Suicide and Crisis Hotline Has Received Nearly 5 Million Combined Calls\, Texts\, and Chats | KFF \n\n\n\nPsychU Suicide Prevention Brochure:Download Brochure \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. URL:https://psychu.org/event/suicide-awareness-prevention-psychu-resource-review-discussion/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/08/Depression_group-therapy_912x506_shutterstock_2321772109.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20230913T120000 DTEND;TZID=America/New_York:20230913T130000 DTSTAMP:20240328T044025 CREATED:20230816T203054Z LAST-MODIFIED:20230914T160627Z UID:10003385-1694606400-1694610000@psychu.org SUMMARY:Defining\, Clarifying\, & Implementing Digital Tools For Mental Health DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n Digital tools are one of the newest therapeutic modalities for the prevention\, management\, or treatment of chronic\, behavior-modifiable disease.1 In this webinar\, Dr. Jake Behrens and Dr. Margaret Emerson will share their expertise in the utilization of digital tools. Together\, they will define digital health tools\, clarify their potential application in clinical practice\, and describe digital tool implementation best practices.\n\n\nObjectives: \n• Define Digital Heath Tools\n• Clarify the Application of Digital Tools in Mental Health Treatment\n• Outline the Implementation of Digital Tools in Clinical Practice\n\n1 Patel NA\, Butte AJ. Characteristics and challenges of the clinical pipeline of digital therapeutics NPJ Digit Med.2020;3:159. \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Jake Behrens\, MD\n CEO & Medical Director\, Regional Director\nEnvision ADHD\, Brightside Health \n \n \n \n\n\n \n \n \n \n Margaret Emerson\, DNP\, APRN\, PMHNP-BC\n Clinical Associate Professor at the University of Nebraska Medical Center\, Omaha\, NE \n \n \n More\n \n Dr. Margaret Emerson is a Clinical Associate Professor at the University of Nebraska Medical Center\, which is the site where she completed her Bachelor\, Master and Doctorate degrees. Dr. Emerson has extensive expertise in the development and delivery of Integrated and Collaborative care modalities in a variety of clinical environments. Notably she was one of the first psychiatric mental health nurse practitioners in the state of Nebraska to serve in the psychiatric consultant role. Her research efforts have focused on improving access to care among the underserved patient populations within the integrative environments through the use of mobile technology. As a result of this work she was selected as an expert panelist for the American Psychiatric Association App Advisory Panel. She is regularly an invited speaker and consultant across the United States to disseminate her expertise in integrated care and use of technology. She most recently was awarded an American Rescue Plan Act grant enabling her to develop one of the first integrated care student health clinics in rural Nebraska. This grant focuses on technology and tailored training to promote exposure and interest in these delivery models.\n \n \n\n\n \n \n \n \n Jason Carter\, PharmD (OPDC)\n Senior Medical Science Liaison\, Neuroscience Field Medical Affairs \n \n \n \n\n\nDr. Jake Behrens and Dr. Margaret Emerson are paid consultants of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC). \nDr. Jason Carter is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC). \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. URL:https://psychu.org/event/defining-clarifying-implementing-digital-tools-for-mental-health/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/08/Digital-Health_912x506-e1695928625612.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20230727T120000 DTEND;TZID=America/New_York:20230727T130000 DTSTAMP:20240328T044026 CREATED:20230602T211916Z LAST-MODIFIED:20230727T143749Z UID:10003966-1690459200-1690462800@psychu.org SUMMARY:Addressing Inequalities In Agitation Among Disinvested Communities With Alzheimer's Disease DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n Agitation is a complex and challenging neuropsychiatric symptom in Alzheimer’s disease1\, and it is associated with increased economic\, healthcare\, individual\, and care partner burden. Unfortunately\, agitation associated with Alzheimer’s disease is highly prevalent and poses significant challenges in accessing effective care\, particularly for individuals from disinvested and underrepresented ethnicities. The expression of agitation associated with Alzheimer’s Disease is increasing in minority older adults\, exacerbating these challenges2. Agitation in Alzheimer’s Disease is associated with increased economic\, healthcare\, individual\, and care partner burden as well.3 In this webinar\, our expert speaker will explore the barriers to treatment access and challenges faced by the medical community in delivering equitable care to agitated individuals with Alzheimer’s Disease from diverse backgrounds.\n\n\nReferences:\n\n Kales\, H. C.\, Gitlin\, L. N.\, & Lyketsos\, C. G. (2015). Assessment and management of behavioral and psychological symptoms of dementia. BMJ (Clinical research ed.)\, https://doi.org/10.1136/bmj.h369\n Babulal\, G. M.\, & Quiroz\, Y. T. (2019). Perspectives on ethnic and racial disparities in Alzheimer’s disease and related dementias: Update and areas of immediate need. Alzheimer’s & Dementia\, 15(2)\, 292-312. https://doi.org/10.1016/j.jalz.2018.09.009\n Anatchkova\, M.\, & Brooks\, A. (2019). Agitation in patients with dementia: a systematic review of epidemiology and association with severity and course. International Psychogeriatrics\, 31(9)\, 1305–1318. https://doi.org/10.1017/S1041610218001898\n \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n April D. Thames\, Ph.D.\n Professor of Psychiatry\, Chief Psychologist of Adult Division (Psychology) at UCLA Department of Psychiatry and Biobehavioral Sciences \n \n \n \n\n\n \n \n \n \n John Awad\, MD (OPDC)\n Senior Medical Science Liaison \n \n \n \n\n\n \n \n \n \n Nneka Okonkwor\, PharmD\, MBA (OPDC)\n Medical Science Liaison \n \n \n \n\n\n\n\n\n\nApril D. Thames\, Ph.D.\, is a paid consultant of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)John Awad\, MD and Nneka Okonkwor\, PharmD\, MBA\, are paid employees of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) and Otsuka America Pharmaceutical\, Inc. (OAPI). Specific PsychU programs may be supported by OPDC\, OAPI and other committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsor or the sponsors of the specific PsychU program in which such opinions are expressed. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as\, nor is it a substitute for\, medical care\, advice\, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC and OAPI. \n US.CORP.X.23.00232\n \n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. \n \n \n \n \n \n \n\n\n\n\n \n \n \n Home\n \n \n \n \n Events\n \n \n \n \n Webinar URL:https://psychu.org/event/addressing-inequalities-in-agitation-among-disinvested-communities-with-alzheimers-disease/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/06/Seniors-playing-chess_912x506_shutterstock_1478620241.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20230719T120000 DTEND;TZID=America/New_York:20230719T130000 DTSTAMP:20240328T044026 CREATED:20230615T200800Z LAST-MODIFIED:20230714T224534Z UID:10003964-1689768000-1689771600@psychu.org SUMMARY:Exploring Unresolved Symptoms In Major Depressive Disorder (MDD): Potential Role Of Norepinephrine DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n Join us for a PsychU webinar exploring unresolved symptoms in major depressive disorder (MDD) and the potential role of norepinephrine\, as part of the monoaminergic theory of depression.\n\n\nDespite the efficacy of first-line anti-depressant treatments in MDD\, many individuals continue to experience unresolved symptoms that may impair their daily functioning and increase the healthcare burden. In fact\, the STAR*D study demonstrated approximately one third of patients with MDD achieved remission following treatment with first-line antidepressants\, highlighting the need to address unresolved and persistent symptoms of depression.1 Recent studies have shown that norepinephrine\, a neurotransmitter which regulates concentration\, energy levels\, and arousal\, may play a crucial role in the persistence of depression symptoms.2\n\n\nPlease join Drs. Roger McIntyre and John Awad as they discuss the potential role of norepinephrine in depression and the challenges of identifying and treating unresolved depression symptoms. Our webinar aims to provide valuable insights into the complex nature of depression and the potential for treatments to address unresolved symptoms of depression.\n\n\nReferences:\n\n Rush AJ et al. Am J Psychiatry. 2006;163:1905-1917\n Maletic V\, et al. Front Psychiatry. 2017;8:42.\n \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Roger S. McIntyre\, MD\, FRCPC\n Professor of Psychiatry and Pharmacology\, University of Toronto\, \nHead of the Mood Disorders Psychopharmacology Unit\, University Health Network\, Toronto\, Canada\n \n \n \n More\n \n Dr. Roger McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network\, Toronto\, Canada.\n\n\nDr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto\, Canada. Dr. McIntyre is also Director as well as Co-Chair of the Scientific Advisory Board of the Depression and Bipolar Support Alliance (DBSA) from Chicago\, Illinois\, USA. Dr. McIntyre is also Professor and Nanshan Scholar at Guangzhou Medical University\, and Adjunct Professor College of Medicine at Korea University. Dr. McIntyre is also Clinical Professor State University of New York (SUNY) Upstate Medical University\, Syracuse\, New York\, USA and Clinical Professor Department of Psychiatry and Neurosciences University of California School of Medicine\, Riverside\, California\, USA. Dr. McIntyre is the founder of the Canadian Rapid Treatment Centre of Excellence (CRTCE).\n\n\nDr. McIntyre was named by Clarivate Analytics in 2014\, 2015\, 2016\, 2017\, 2018\, 2019 and 2020 as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre has published more than 650 articles/manuscripts and has edited and/or co-edited several textbooks on mood disorders.\n\n\nDr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders\, notably cognitive function\, and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.\n\n\nDr. McIntyre is extensively involved in medical education. He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto\, Department of Psychiatry and has been a recipient of the joint Canadian Psychiatric Association (CPA) / Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada.\n\n\nDr. McIntyre is the lead author for the Florida Best Practice Psychotherapeutic Medication Guidelines for Adults with Major Depressive Disorder and Bipolar Disorder. Dr. McIntyre is also a contributor to the CANMAT guidelines for the treatment of Depressive Disorders and Bipolar Disorders.\n\n\nDr. McIntyre completed his medical degree at Dalhousie University. He received his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.\n \n \n\n\n \n \n \n \n John Awad\, MD (OPDC)\n Senior Medical Science Liaison \n \n \n \n\n\n\n\n\n\n\n\nSpeaker Roger S. McIntyre\, MD\, FRCPC is a paid consultant for Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) Speaker John Awad\, MD is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n Webinar Pre-Polling\n \n \n \n \n \n \n \n \n \n \n Please fill out this survey before the webinar! \n \n \n \n \n \n In your clinical experience\, which of the following unmet needs have you recognized with antidepressant treatment (ADT) pharmacotherapy?\n \n \n Limited specific efficacy with first-line therapies\n \n \n \n Intolerable side effects\n \n \n \n Inconsistent treatment response\n \n \n \n Relatively slow onset of action\n \n \n \n Need for second-line treatment modalities\n How familiar are you with monoaminergic dysregulation in MDD?\n \n \n Not at all familiar\n \n \n \n Somewhat familiar\n \n \n \n Familiar\n \n \n \n Very familiar\n \n \n \n Extremely familiar\n How likely are you to consider modulation of norepinephrine when prescribing treatment to patients with unresolved symptoms?\n \n \n Never\n \n \n \n Rarely\n \n \n \n Sometimes\n \n \n \n Often\n \n \n \n Always\n In your clinical practice\, what is your preferred second-line treatment strategy when your first-choice ADT is ineffective?\n \n \n Increase dose and optimize current ADT\n \n \n \n Switch to a different ADT (SSRI or SNRI)\n \n \n \n Switch to a non-ADT (DNRI)\n \n \n \n Stay on same ADT and combine with another ADT (SSRI or SNRI)\n \n \n \n Stay on same ADT and augment with a non-ADT (DNRI)\n \n \n \n Stay on same ADT and augment with a non-ADT (AAP)\n In your clinical practice\, what is your preferred adjunctive strategy for patients who have a partial response to monotherapy?\n \n \n Atypical antipsychotics\n \n \n \n Mood stabilizers\n \n \n \n Benzodiazepines\n \n \n \n Psychotherapy\n Which of the following receptors are active during low NE states?\n \n \n α1A\n \n \n \n α1B\n \n \n \n α2B\n \n \n \n α2C\n \n \n \n β2\n \n \n \n \n \n \n \n \n \n \n \n \n Δ \n \n\n \n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. URL:https://psychu.org/event/exploring-unresolved-symptoms-in-major-depressive-disorder-mdd-potential-role-of-norepinephrine/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/06/Depressed-lady_912x506_shutterstock_1900247404.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20230713T120000 DTEND;TZID=America/New_York:20230713T130000 DTSTAMP:20240328T044026 CREATED:20230601T135955Z LAST-MODIFIED:20230713T145453Z UID:10003968-1689249600-1689253200@psychu.org SUMMARY:Long-Acting Injectables For The Treatment Of Bipolar I Disorder: Relevant Questions From Providers DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n Join us for this lively discussion with Dr. Joseph Goldberg and Dr. Mauricio Tohen regarding long-acting injectables (LAIs) in the treatment of bipolar I disorder. This moderated session will explore perception\, preferences\, challenges\, and treatment goals for both patients and providers. Discussants will review provider and patient centric perspectives in selecting therapy\, plus potential strategies to assess preferences regarding new preventative treatments such as mode of administration\, dosing regimen and treatment-related determinants of adherence.\n\n\nObjectives:\n\n Describe the challenges to long-term treatment and the importance of management options in patients diagnosed with Bipolar I Disorder (BP-I)\n Discuss the pros and cons of LAIs for patients living with BP-I\, from the provider and patient perspective\n Understand strategies to aid in shared decision making between providers and patients when considering LAIs\n \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Joseph Goldberg\, MD\n Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai\n \n \n \n More\n \n Dr. Goldberg currently serves as the Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai and serves on the Board of Directors for the American Society of Clinical Psychopharmacology. Dr. Goldberg has published over 200 peer-reviewed papers on topics related to the treatment and clinical features of bipolar disorder\, as well as three books on bipolar disorder and psychopharmacology.\n \n \n\n\n \n \n \n \n Mauricio Tohen\, MD\, DrPH\, MBA\n Chairman\, Department of Psychiatry\, University Distinguished Professor\, University of New Mexico Health Science Center \n \n \n \n More\n \n Mauricio Tohen\, MD\, DrPH\, MBA\, is a University Distinguished Professor and Chairman of the Department of Psychiatry at the University of New Mexico Health Science Center\, Albuquerque NM. From 2009 to 2013 he was a Professor of Psychiatry and The Krus Endowed Chair in Psychiatry at the University of Texas Health Science Center at San Antonio. Dr. Tohen received his medical degree from the National University of Mexico and his Doctor of Public Health degree in Epidemiology from Harvard University. His postdoctoral training included a residency in Psychiatry at the University of Toronto\, a clinical fellowship at McLean Hospital and Harvard Medical School\, and a teaching fellowship in Epidemiology at the Harvard School of Public Health. From 1988 to 1997\, Dr. Tohen was the Clinical Director of the Bipolar and Psychotic Disorders Program at McLean Hospital. From 1997 to 2008 he was a member of Lilly Research Laboratories reaching the senior-most scientific level of Distinguished Lilly Scholar. In 2009 he joined the University of Texas Health Science Center at San Antonio as the Head of the Division of Mood and Anxiety Disorders. Dr. Tohen received a National Service Award in Psychiatric Epidemiology from the National Institute of Mental Health (NIMH) and Harvard University. He also received a FIRST award from the NIMH\, the Pope Award from McLean Hospital\, and a NARSAD Young Investigator Award and the Simon Bolivar Award from the American Psychiatric Association. In 2014 he was named by Thomson Reuter’s “The World’s Most Influential Scientific Minds\, 2014”. Honorees were the scientists who ranked in the Top 1 percent by citations of their published work in 21 broad fields between 2002 and 2012.\n \n \n\n\n \n \n \n \n Michael Aldape\, PhD (OPDC)\n Senior Medical Science Liaison \n \n \n \n\n\nJoseph Goldberg\, MD and Mauricio Tohen\, MD\, DrPH\, MBA are paid consultants of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)Michael Aldape\, PhD is a paid employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) and Otsuka America Pharmaceutical\, Inc. (OAPI). Specific PsychU programs may be supported by OPDC\, OAPI and other committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsor or the sponsors of the specific PsychU program in which such opinions are expressed. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as\, nor is it a substitute for\, medical care\, advice\, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC and OAPI. \n US.CORP.X.23.00219\n \n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. URL:https://psychu.org/event/long-acting-injectables-for-the-treatment-of-bipolar-i-disorder-relevant-questions-from-providers/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/05/LAI_physician-giving-an-injection_912x506_shutterstock_2119856291.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20230622T120000 DTEND;TZID=America/New_York:20230622T130000 DTSTAMP:20240328T044026 CREATED:20230522T132430Z LAST-MODIFIED:20230622T145609Z UID:10003970-1687435200-1687438800@psychu.org SUMMARY:The Curious Case Of Metabolic Dysfunction In Schizophrenia: Who’s Susceptible & Why? DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n A recent article1 published in World Psychiatry evaluated the mid and long term metabolic side effects of 31 antipsychotic drugs and confirmed that antipsychotic drugs differ in their propensity to induce metabolic side effects. Given that patients with schizophrenia often need lifelong treatment\, careful consideration should be given when choosing an antipsychotic. Join a multidisciplinary panel including two metabolic-expert psychiatrists\, a psychiatric nurse practitioner\, and a licensed social worker highlighting:\n\n The heightened metabolic risk in drug-naïve individuals\, the added risk when treating with antipsychotics\n What cardiometabolic parameters are important to measure (and why)\n What can be done to mitigate metabolic risks when considering risk/benefit\n Education regarding how the brain and body process sugar and implications for energy production will be discussed\n Evolution of metabolic guidelines and where we are headed\n\n\nReference:\n\n Burschinski A et al. World Psychiatry 2023; 22 :116-128\n \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Christoph Correll\, MD\n Chair of the Department of Child and Adolescent Psychiatry\, Psychosomatic Medicine and Psychotherapy\, Charité Universitätsmedizin Berlin\, Campus Virchow\, Berlin\, Germany. Professor of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell\, New York\, USA. \n \n \n More\n \n Professor Correll’s research and clinical work focus on the identification\, characterization and treatment of youth with severe mental illness\, including psychotic and mood disorders\, spanning all disease stages from the prodrome to first and multi-episode illness and up to refractory illness.\nHe further focuses on psychopharmacology\, epidemiology\, comparative effectiveness\, meta-analyses\, the risk–benefit evaluation of psychotropic medications\, and the interface between physical health and mental health.\n \n \n\n\n \n \n \n \n William Wirshing\, MD\n Clinical Professor of Psychiatry\, Keck USC School of Medicine; and Medical Director of Exodus Recovery\, Inc. in Los Angeles\, CA \n \n \n More\n \n Dr. William Wirshing is a Clinical Professor of Psychiatry at the Keck USC School of Medicine and Medical Director of Exodus Recovery\, Inc in Los Angeles\, where he provides psychiatric and chemical dependency care. His 40-year career has focused on the treatment of persons with schizophrenia and in particular the toxic consequences of putative antipsychotic compounds. Dr. Wirshing and his co-investigators at UCLA and the West Los Angeles VA Medical Center\, pioneered the early studies leading to the discovery of metabolic side effects that became a veritable hallmark of the newer class of agents. His findings led to the development of the American Psychiatric Association and American Diabetes Association consensus guideline to appropriately monitor patients on atypical antipsychotic agents.\n \n \n\n\n \n \n \n \n Michael Townsend\, MA\, LSW/LCSW\n Deputy Chief Executive Officer\, Gateway Counseling Center \n \n \n More\n \n Mr. Townsend\, is the Deputy Chief Executive Officer at Gateway Counseling Center where he assists the Chief Executive Officer (CEO) with managing and directing the organization towards its primary objectives\, serves as a member of the Boardof Directors\, as well as the Chair of Audit Committee of the Mental Health Association in New York\, and is also the President of GCC Transportation\, LLC\, which directs transportation services to the transit disabled and medically frail.\n \n \n\n\n \n \n \n \n Darcy Leon\, PMHNP-BC \n Psychiatric Nurse Practitioner \n \n \n More\n \n Darcy Leon is a psychiatric nurse practitioner currently working in outpatient psychiatry in Tarrytown\, NY. She specializes in the treatment of mood disorders\, traumatic brain injury\, substance use disorders\, and treatment-refractory psychiatric illnesses. Darcy also has a specific interest in psychodynamic psychopharmacology\, which she employs to better connect patients with the ways their personal experiences interact with medication treatments.\n \n \n\n\n \n \n \n \n Laura Brennan\, PhD (OPDC)\n Medical Science Liaison \n \n \n \n\n\n\n\n\n\nChristoph Correll\, MD\, William Wirshing\, MD\, Michael Townsend MA\, LMSW and Darcy Leon\, PMHNP-BC are paid consultants of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)Laura Brennan\, PhD is a paid employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Early Intervention In Schizophrenia: Targeting Metabolic Dysfunction\n \n On-Demand Webinar November 7\, 2017\n \n Increasingly\, schizophrenia is considered a medical psychiatric disease. There is evidence that metabolic changes occur within the first episode of psychosis\, and within the first few weeks of initiating antipsychotic… \n \n \n Mental Health & Metabolic Wellness Series: Focus On Weight & Obesity\n \n Video October 9\, 2017\n \n During this presentation\, Charles Nguyen\, MD\, provided a brief overview of the obesity epidemic and how obesity may be a contributing factor to other serious medical conditions\, including the potential… URL:https://psychu.org/event/the-curious-case-of-metabolic-dysfunction-in-schizophrenia-whos-susceptible-why/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/png:https://psychu.org/wp-content/uploads/2023/05/Brain-Medicine_Pill_head_912x506_shutterstock_235393648.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20230621T120000 DTEND;TZID=America/New_York:20230621T130000 DTSTAMP:20240328T044026 CREATED:20230511T144347Z LAST-MODIFIED:20230621T155755Z UID:10003971-1687348800-1687352400@psychu.org SUMMARY:New ICD-10-CM Dementia Codes For Agitation In Alzheimer’s Dementia DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n Effective October 1\, 2022\, updates to the International Classification of Disease\, 10th Revision clinical modification (ICD-10 CM) added new coding specificity options for recording diagnoses of dementia. The expanded codes may be used to capture details of dementia type\, severity and more fully identify types of neuropsychiatric symptoms of dementia. This presentation will introduce the improved coding options and describe the coding structure format used in the updated dementia code sections. New code guidance for agitation in Alzheimer’s dementia will be compared to the International Psychogeriatric Association definition of agitation cognitive disorders. Dr. Carolyn Clevenger will discuss use of the codes in practice and the potential implications of the dementia code revisions on providing care for persons living with dementia. \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Carolyn Clevenger\, DNP\, RN\, GNP-BC\, AGPCNP-BC\, FAANP\, FGSA\n Professor of Transformative Clinical Practice\, Emory University School of Nursing\, Clinical Director and Gerontological Nurse Practitioner at Integrated Memory Care Clinic \n \n \n More\n \n Carolyn Clevenger DNP\, RN\, GNP-BC\, AGPCNP-BC\, FAANP\, FGSA\, is Professor of Transformative Clinical Practice at the Emory University School of Nursing in Atlanta\, Georgia. She serves as Clinical Director and Gerontological Nurse Practitioner at Emory’s Integrated Memory Care Clinic\, a patient-centered medical home providing integrated memory care and primary care for persons living with dementia. She is a Past President of the Gerontological Advanced Practice Nurses Association\, and Fellow of the American Association of Nurse Practitioners (AANP) and the Gerontological Society of America.\n \n \n\n\n \n \n \n \n Mike Crooks\, PharmD\, BCGP (OPDC)\n Senior Long-Term Care Medical Science Liaison \n \n \n \n\n\nCarolyn Clevenger DNP\, RN\, GNP-BC\, AGPCNP-BC\, FAANP\, FGSA is a paid consultant of Otsuka Pharmaceutical Development & Commercialization\, Inc.Mike Crooks\, PharmD CGP is a paid employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. URL:https://psychu.org/event/new-icd-10-cm-dementia-codes-for-agitation-in-alzheimers-dementia/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/05/Alzheimers-Dimentia_nurse_patient_912x506_shutterstock_1383653003.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20230614T120000 DTEND;TZID=America/New_York:20230614T130000 DTSTAMP:20240328T044026 CREATED:20230518T174248Z LAST-MODIFIED:20230609T145535Z UID:10003972-1686744000-1686747600@psychu.org SUMMARY:Pseudobulbar Affect (PBA) In Geriatric & Long-Term Care Patients DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n PBA is a neurologic condition that occurs secondary to a variety of otherwise unrelated neurologic conditions and is characterized by sudden\, frequent\, uncontrollable episodes of laughing and/or crying.1\,2 Residents in long-term care settings with PBA symptoms may have different characteristics with their medication usage or behavioral symptoms compared to those residents without PBA symptoms.3\,4 In this webinar\, our panelists will be reviewing PBA characteristics\, neurocircuitry and pathophysiology\, PBA prevalence\, the impact of PBA on patients and assessment of PBA symptoms.\n\n\nReferences:\n\n1. Cummings JL\, et al. CNS Spectr. 2006;11(6):1-7\n2. Wortzel HS\, et al. CNS Drugs. 2008; 22(7):531-545\n3. Foley K et al. Int J Geriatr Psychiatry. 2016;31:694-701\n4. Zarowitz BJ\, et al. Consultant Pharm. 2013;28:713-22 \n\n\n \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Justin Rash\, PharmD\, BCGP (OPDC)\n Senior Medical Science Liaison \n \n \n \n\n\n \n \n \n \n Michelle Lavagnino\, DrPH(c) (OPDC)\n Medical Science Liaison\, Long-term Care \n \n \n \n\n\nJustin Rash and Michelle Lavagnino are employees of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. URL:https://psychu.org/event/pseudobulbar-affect-pba-in-geriatric-long-term-care-patients/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/05/man-looking-upset912x506_shutterstock_1800887224.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20230524T120000 DTEND;TZID=America/New_York:20230524T130000 DTSTAMP:20240328T044026 CREATED:20230331T191324Z LAST-MODIFIED:20230524T155030Z UID:10003356-1684929600-1684933200@psychu.org SUMMARY:Faces Of Depression In Primary Care: Depression Symptomology & Functional Outcomes From Early To Late Adulthood DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n Depression is a common disorder and leading cause of disability worldwide\, which impacts an estimated 280 million individuals or ~5% of the adult population.1 Primary care clinicians are often the first access point for individuals experiencing behavioral health symptoms\, particularly depression.2 Although they have the training and expertise required to address mental illnesses\, differences in presentation across the lifespan and presence of medical comorbidities can complicate recognition and effective treatment of major depressive disorder. \nIn this Faces of Depression webinar\, Dr. Beth DiNapoli moderates an enlightening discussion on various presentations of depression across the adult lifespan with primary care physician and clinical researcher Dr. C. Brendan Montano. They will share perspectives on the role of primary care in identifying\, assessing\, and managing major depressive disorder across the lifespan. An emphasis on some of the unique complexities within the primary care landscape and an examination of the burden of disease with respect to functional outcomes will be provided. Finally\, the various treatments for depression and the role they may play in overall depression improvement and functionality will be highlighted. Join us for this opportunity to learn and grow as we all strive to improve our mental health …. together!\n\n\nReferences:\n\n1. World Health Organization 2022 website: https://www.who.int/news-room/fact-sheets/detail/depression\n2. Jetty et al. 2021 Assessing Primary Care Contributions to Behavioral Health: A Cross-sectional Study Using Medical Expenditure Panel Survey; Journal of Primary Care & Community Health Volume 12: 1–6.\n \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n C. Brendan Montano\, MD\, PC\n Director and Principal Investigator for Connecticut Clinical Research in Cromwell\, Connecticut \n \n \n More\n \n Dr. Montano is Director and Principal Investigator for Connecticut Clinical Research in Cromwell\, Connecticut\, where he also holds a private practice in internal medicine\, specializing in preventative medicine and mood disorders. In addition\, he is an attending physician at Middlesex Memorial Hospital in Middletown\, Connecticut.\n \n \n\n\n \n \n \n \n Elizabeth DiNapoli\, PhD (OPDC)\n Senior Medical Science Liaison \n \n \n More\n \n Dr. DiNapoli earned her PhD from the University of Alabama.\n \n \n\n\nC. Brendan Montano is a paid consultant of Otsuka Pharmaceutical Development & Commercialization\, Inc.(OPDC). Beth DiNapoli is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Assessing Cognitive Impairment\, Depression\, & Functionality In Older Adults\n \n Interview August 10\, 2022\n \n Cognitive impairment\, depression\, and functional decline are all common in older adults. Therefore\, it is important for care providers to understand how to screen/evaluate for each of these domains in… \n \n \n Patient Health Questionnaire 9 (PHQ-9)\n \n Downloadable Resource October 30\, 2017\n \n The Patient Health Questionnaire 9 is a self-administered 9-item scale for assessing and monitoring depression severity. It is derived from the depression questions within the full Patient Health Questionnaire (PHQ)…. URL:https://psychu.org/event/faces-of-depression-in-primary-care-depression-symptomology-functional-outcomes-from-early-to-late-adulthood/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/03/psysician-and-patiend_912x506_shutterstock_482665693.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20230518T120000 DTEND;TZID=America/New_York:20230518T130000 DTSTAMP:20240328T044026 CREATED:20230417T222511Z LAST-MODIFIED:20230518T183641Z UID:10003959-1684411200-1684414800@psychu.org SUMMARY:Supporting Individuals Living With A Mental Health Condition Through 988 & Mental Health Education DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n The month of May is designated as Mental Health Awareness Month\, and it is the perfect time to pause and reflect on mental health issues\, challenges\, and opportunities. In a recent survey\, an overwhelming majority of the public (90%) think that there is a mental health crisis in the U.S. today\, with most people saying the opioid epidemic\, mental health issues in children and teenagers\, and severe mental illness are at crisis levels in the country.1 Join us in this webinar as our panelists discuss their experiences on preparing for a mental health crisis\, share their perspectives on implementation and utility of 988\, impact on emergency responders\, and the importance of mental health education and training. \n\nReference:\n1. KFF/CNN Mental Health In America Survey. https://www.kff.org/report-section/kff-cnn-mental-health-in-america-survey-findings/. Accessed on March 2023. \n \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Dwayne Mayes\, MS\n Program Director of the Recovery Network & Peer Training Program at the Mental Health Association of Westchester; former board member of the International Association of Peer Specialists\n\n \n \n \n \n\n\n \n \n \n \n Laura Brennan\, PhD (OPDC)\n Medical Science Liaison \n \n \n \n\n\n \n \n \n \n Dennis Sholler\, PhD (OPDC)\n Senior Medical Science Liaison\, CNS \n \n \n \n\n\nDwayne Mayes\, MS is paid consultant of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)Laura Brennan\, PhD and Dennis Sholler\, PhD are employees of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. URL:https://psychu.org/event/supporting-individuals-living-with-a-mental-health-condition-through-988-mental-health-education/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/04/group-of-teens_912x506_shutterstock_2169268331.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20230511T120000 DTEND;TZID=America/New_York:20230511T130000 DTSTAMP:20240328T044026 CREATED:20230322T202519Z LAST-MODIFIED:20230425T170348Z UID:10003945-1683806400-1683810000@psychu.org SUMMARY:Beyond Memory Loss: Optimizing The Role Of Primary Care In Assessing & Treating Agitation In Alzheimer’s Dementia DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n Challenges in the treatment of agitation associated with Alzheimer’s Dementia (AAD) presents across multiple treatment settings. As the prevalence of Alzheimer’s Dementia continues to significantly increase\, Primary Care will play an important role in not only assessing for cognitive declines in older adults but also in managing the diagnosis and treatment of AAD. This webinar will dive into the unmet needs within this patient population and feature experts in the management of AAD within the primary care setting. Specifically\, presenters will review the prevalence of AAD\, describe challenges in diagnosing AAD\, and explore the potential pathobiological correlates in AAD. The webinar will discuss the clinical and humanistic burden of AAD\, as well as highlight the current guidelines for nonpharmacological and pharmacological treatments of this complex and prominent complication of an already devastating disease. \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n C. Brendan Montano\, MD\, PC\n Director and Principal Investigator for Connecticut Clinical Research in Cromwell\, Connecticut \n \n \n More\n \n Dr. Montano is Director and Principal Investigator for Connecticut Clinical Research in Cromwell\, Connecticut\, where he also holds a private practice in internal medicine\, specializing in preventative medicine and mood disorders. In addition\, he is an attending physician at Middlesex Memorial Hospital in Middletown\, Connecticut.\n \n \n\n\n \n \n \n \n Elika Hefazi\, PharmD\, BCPP (OPDC)\n Medical Science Liaison \n \n \n \n\n\n \n \n \n \n Elizabeth DiNapoli\, PhD (OPDC)\n Senior Medical Science Liaison \n \n \n More\n \n Dr. DiNapoli earned her PhD from the University of Alabama.\n \n \n\n\nSpeaker Dr. C. Brendan Montano is a paid consultant for Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)Speakers Elika Hefazi\, PharmD\, BCPP and Beth DiNapoli\, PhD are employees of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. URL:https://psychu.org/event/beyond-memory-loss-optimizing-the-role-of-primary-care-in-assessing-treating-agitation-in-alzheimers-dementia/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/03/Shutterstock_1562123143.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20230426T120000 DTEND;TZID=America/New_York:20230426T130000 DTSTAMP:20240328T044026 CREATED:20230319T011931Z LAST-MODIFIED:20230426T154731Z UID:10003939-1682510400-1682514000@psychu.org SUMMARY:Digital Mental Health Treatments: The Role Of Neurobehavioral Therapies In Major Depressive Disorder (MDD) DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n There is a significant unmet need for patients with Major Depressive Disorder (MDD) who fail to achieve an adequate response to current treatments. As our understanding of the biology of depression evolves\, novel treatment targets are emerging. Neurobehavioral therapies (NBTs) that affect changes in potential mechanisms underlying depression are being explored. In this webinar\, Dr. Robin Nelson\, MD and Dr. Sandeep Vaishnavi\, MD\, PhD\, will review the potential importance of neurocircuitry and neuroplasticity in MDD. They will also discuss the potential utility of using digital mental health treatments (DMHTs) to target neurobiological emotional control systems. \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Robin Nelson\, MD\n Psychiatrist\, DGR Behavioral Health LLC & Caron Treatment Centers \n \n \n More\n \n Psychiatrist at DGR Comprehensive Behavioral Health LLC in Wyomissing\, PA\, and an attending psychiatrist at the Caron Foundation Treatment Center in Wernersville\, PA. Dr. Nelson received his MD from Duke University’s School of Medicine. He completed his residency in Duke University’s Psychiatric Residency Education Program. Dr. Nelson is board certified by the American Board of Psychiatry and Neurology.\n \n \n\n\n \n \n \n \n Sandeep Vaishnavi\, MD\, PhD\n Faculty\, Duke Institute for Brain Sciences (DIBS)\, Duke University \n \n \n More\n \n Dr. Vaishnavi completed his MD and PhD at the University of Alabama at Birmingham School of Medicine\, and his residency at Duke University. He is board-certified in psychiatry and certified in Behavioral Neurology & Neuropsychiatry by the United Council for Neurologic Subspecialties. He is affiliated with the Duke Institute for Brain Sciences. His research interests include investigating methods to enhance neural plasticity and resilience with brain stimulation\, digital therapeutics\, and evidence-based stress management tools. He is a best-selling author of The Traumatized Brain: A Family Guide to Understanding Mood\, Memory\, and Behavior after Brain Injury. His newest book\, Healing the Traumatized Brain: Coping after Concussion and Other Brain Injuries\, will be released in July 2023.\n \n \n\n\n \n \n \n \n Mark Tacelosky\, PharmD (OPDC)\n Senior Medical Science Liaison \n \n \n \n\n\nSpeakers Robin Nelson\, MD and Sandeep Vaishnavi\, MD\, PhD are paid consultants of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)Speaker Mark Tacelosky\, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. URL:https://psychu.org/event/digital-mental-health-treatments-the-role-of-neurobehavioral-therapies-in-major-depressive-disorder-mdd/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2021/01/Shutterstock_514313119.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20230420T170000 DTEND;TZID=America/New_York:20230420T180000 DTSTAMP:20240328T044026 CREATED:20230328T224825Z LAST-MODIFIED:20230420T213618Z UID:10003952-1682010000-1682013600@psychu.org SUMMARY:Behavioral Health Trends Affecting Payers DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n The evolving mental healthcare landscape has a marked impact on payers. Psychiatrist Dr. Don Fowls\, managed care expert and healthcare consultant\, has worked with payers across the country. In this discussion\, the speakers will review current behavioral health trends affecting payers. \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Don J Fowls\, MD\n Payer Section Advisor; President of Don Fowls & Associates in Scottsdale\, AZ; Senior Advisor\, Alera Health; Senior Advisor\, The Menges Group; Past President and Legislative Chair\, Arizona Psychiatric Society \n \n \n \n\n\n \n \n \n \n Madeline Shurtleff\, PharmD (OPDC)\n Managed Market Liaison \n \n \n More\n \n Dr. Shurtleff is a clinical pharmacist with experience in managed care and retail pharmacy. She has extensive knowledge in Medicaid and Medicare pharmacy operations and regulatory requirements. Dr. Shurtleff received her Doctor of Pharmacy (PharmD)\, Business Minor\, and Leadership Minor from the University of Rhode Island. She is a licensed pharmacist in Illinois and Arizona.\n \n \n\n\nDon J Fowls\, MD is paid consultant of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)Madeline Shurtleff\, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. URL:https://psychu.org/event/behavioral-health-trends-affecting-payers/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/03/brain_man_money_912x506_shutterstock_527785105.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20230406T120000 DTEND;TZID=America/New_York:20230406T130000 DTSTAMP:20240328T044026 CREATED:20230227T184253Z LAST-MODIFIED:20230406T160920Z UID:10003926-1680782400-1680786000@psychu.org SUMMARY:Linking Neural Circuits To Dysfunction In Schizophrenia DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n We have known dysfunction in certain neural circuit pathways ultimately led to symptoms in schizophrenia. These aberrant pathways caused downstream neurotransmitter dysregulation that formed the foundation of the dopamine hypothesis. Advances in imaging technology in the recent decade led to investigations into these neural circuit pathways\, yielding surprising results. This webinar will feature two experts in the field of schizophrenia who will discuss how these neural pathways interact\, as observed from newer imaging data. The results may warrant revision of our understanding of the dopamine hypothesis. \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Christoph Correll\, MD\n Chair of the Department of Child and Adolescent Psychiatry\, Psychosomatic Medicine and Psychotherapy\, Charité Universitätsmedizin Berlin\, Campus Virchow\, Berlin\, Germany. Professor of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell\, New York\, USA. \n \n \n More\n \n Professor Correll’s research and clinical work focus on the identification\, characterization and treatment of youth with severe mental illness\, including psychotic and mood disorders\, spanning all disease stages from the prodrome to first and multi-episode illness and up to refractory illness.\nHe further focuses on psychopharmacology\, epidemiology\, comparative effectiveness\, meta-analyses\, the risk–benefit evaluation of psychotropic medications\, and the interface between physical health and mental health.\n \n \n\n\n \n \n \n \n William Wirshing\, MD\n Clinical Professor of Psychiatry\, Keck USC School of Medicine; and Medical Director of Exodus Recovery\, Inc. in Los Angeles\, CA \n \n \n More\n \n Dr. William Wirshing is a Clinical Professor of Psychiatry at the Keck USC School of Medicine and Medical Director of Exodus Recovery\, Inc in Los Angeles\, where he provides psychiatric and chemical dependency care. His 40-year career has focused on the treatment of persons with schizophrenia and in particular the toxic consequences of putative antipsychotic compounds. Dr. Wirshing and his co-investigators at UCLA and the West Los Angeles VA Medical Center\, pioneered the early studies leading to the discovery of metabolic side effects that became a veritable hallmark of the newer class of agents. His findings led to the development of the American Psychiatric Association and American Diabetes Association consensus guideline to appropriately monitor patients on atypical antipsychotic agents.\n \n \n\n\n \n \n \n \n Elika Hefazi\, PharmD\, BCPP (OPDC)\n Medical Science Liaison \n \n \n \n\n\nSpeakers Christoph Correll\, MD and William Wirshing\, MD are paid consultants for Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)Speaker Elika Hefazi\, PharmD\, BCPP is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. URL:https://psychu.org/event/linking-neural-circuits-to-dysfunction-in-schizophrenia/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/02/neurfunctions_912x506_shutterstock_463026592.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20230330T120000 DTEND;TZID=America/New_York:20230330T130000 DTSTAMP:20240328T044026 CREATED:20230223T211747Z LAST-MODIFIED:20230330T134940Z UID:10003921-1680177600-1680181200@psychu.org SUMMARY:Prioritizing Goals Of Treatment In Patients Diagnosed With Bipolar I Disorder: Results From A US Patient Survey Using Best-Worst Scaling DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n When treating people with bipolar disorder it is important to understand the patient’s perception and prioritization of their goals of treatment. This webinar will discuss how to develop strategies to assess patient preferences regarding new preventative treatments such as mode of administration and dosing regimen\, and explore potential differences in goals of treatment and preferences among selected subgroups of patients with BP-I. Together the presenters will review the results of a survey that asks these questions of people diagnosed with bipolar I disorder and discuss not only the results and outcomes but the potential clinical implications. \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Joseph Goldberg\, MD\n Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai\n \n \n \n More\n \n Dr. Goldberg currently serves as the Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai and serves on the Board of Directors for the American Society of Clinical Psychopharmacology. Dr. Goldberg has published over 200 peer-reviewed papers on topics related to the treatment and clinical features of bipolar disorder\, as well as three books on bipolar disorder and psychopharmacology.\n \n \n\n\n \n \n \n \n Karimah S. B. Lynum\, PharmD\, MBA\, BCPP\n Medical Director\, US Medical Affairs\, Neuroscience\, Otsuka America Pharmaceutical \n \n \n More\n \n Dr. Lynum is a Medical Director in the US Medical Affairs Neuroscience division at Otsuka America Pharmaceutical. After earning her Doctor of Pharmacy degree from Florida A&M University\, she began her career at the Philadelphia VA Medical Center as a Clinical Pharmacy Specialist in Psychiatry. She is a board-certified Psychiatric Pharmacist and has a Master of Business Administration degree from Drexel University’s LeBow College of Business. Dr. Lynum leads medical strategy and provides her scientific expertise and support on clinical trial design\, scientific communications\, and other research-related activities.\n \n \n\n\nSpeaker Joseph Goldberg is a paid consultant of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)Speaker Karimah Lynum is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. URL:https://psychu.org/event/prioritizing-goals-of-treatment-in-patients-diagnosed-with-bipolar-i-disorder-results-from-a-us-patient-survey-using-best-worst-scaling/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/02/Shutterstock_654344257.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20230216T120000 DTEND;TZID=America/New_York:20230216T130000 DTSTAMP:20240328T044026 CREATED:20221203T185114Z LAST-MODIFIED:20230216T191128Z UID:10003308-1676548800-1676552400@psychu.org SUMMARY:Addressing Unresolved Symptoms of Major Depressive Disorder (MDD): The Importance of Norepinephrine\, Serotonin\, and Dopamine Modulation DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n Join the PsychU community for this exciting webinar featuring experts in psychiatry\, Joseph Goldberg and Vladimir Maletic\, as they describe aspects of pathophysiology in major depressive disorder. An emphasis will be placed on the role of several monoamine neurotransmitter systems including norepinephrine\, serotonin\, and dopamine. Drs. Goldberg and Maletic will highlight the burden of disease in depression and discuss current guideline recommendations on MDD treatments\, including considerations for augmentation strategies. Guided by moderator\, Rachel Self\, they will discuss the current psychiatry treatment landscape and provide context around recent publications raising questions regarding depression pathophysiology and the monoamine model. \nJoin us for an exciting and informative dialogue on the pathophysiology of depression and treatment recommendations for those with unresolved symptoms! \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Joseph Goldberg\, MD\n Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai\n \n \n \n More\n \n Dr. Goldberg currently serves as the Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai and serves on the Board of Directors for the American Society of Clinical Psychopharmacology. Dr. Goldberg has published over 200 peer-reviewed papers on topics related to the treatment and clinical features of bipolar disorder\, as well as three books on bipolar disorder and psychopharmacology.\n \n \n\n\n \n \n \n \n Vladimir Maletic\, MD\n Serves as Clinical Professor\, Psychiatry/Behavioral Science\, University of South Carolina School of Medicine Greenville\, SC \n \n \n More\n \n Vladimir Maletic\, MD serves as Clinical Professor\, Psychiatry/Behavioral Science\, School of Medicine Greenville\, SC and has been rated as Best Doctors of the America Registry and Psychiatrist of the year. Dr. Maletic received the Upjohn Achievement Award and Student Council teaching award and faculty award for teaching achievement. He also has received the Medical School Award for Academic Achievement.\n \n \n\n\n \n \n \n \n Rachel Self\, PhD\, MS (OPDC)\n Medical Science Director\, Neuroscience Field Medical Affairs \n \n \n More\n \n \n\nRachel Self\, PhD\, MS is a Medical Science Director for Otsuka’s Neuroscience Field Medical Affairs\, neuroscientist\, & wellness advocate\n\n\n \n \n\n\nSpeakers Joseph Goldberg\, MD and Vladimir Maletic\, MD\, MS are paid consultants for Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)Speaker Rachel Self\, PhD\, MS is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. URL:https://psychu.org/event/addressing-unresolved-symptoms-of-major-depressive-disorder-mddthe-importance-of-norepinephrine-serotonin-and-dopamine-modulation/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2022/12/MDD_912x506_shutterstock_1228163713.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20230126T120000 DTEND;TZID=America/New_York:20230126T130000 DTSTAMP:20240328T044026 CREATED:20221117T195630Z LAST-MODIFIED:20230124T214657Z UID:10003302-1674734400-1674738000@psychu.org SUMMARY:Pharmacokinetics\, Plasma Concentrations & (Their) Clinical Relevance DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n Pharmacokinetics refers to the study of how drugs are processed by the body. These processes play an important role in mental health treatments\, and can vary due to several factors\, ultimately impacting treatment of mental health. In this webinar\, we will first provide an overview of pharmacokinetics and pharmacodynamics. Then\, we will discuss the differences between pharmacokinetics based on different medication formulations\, including the differences between oral and long-acting injectable formulations. Finally\, the importance of pharmacokinetics and plasma concentration monitoring will be discussed as it relates to the clinical setting. \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Stephen R. Saklad\, PharmD\, BCPP\n Director\, Psychiatric Pharmacy Program\, UT Health Science Center San Antonio; Clinical Professor\, UTHSCSA\, School of Medicine\, Pharmacotherapy Education & Research Center\, The University of Texas at Austin College of Pharmacy; and Clinical Pharmacologist\, San Antonio State Hospital\, Texas Department of State Health Services \n \n \n More\n \n Stephen Saklad\, PharmD is a Clinical Professor of Pharmacotherapy and Adjoint Professor\, School of Medicine\, and Director\, Psychiatric Pharmacy Program at the University of Texas\, and a Clinical Pharmacologist for the San Antonio State Hospital\, Texas Department of State Health Services. He received the UT Austin College of Pharmacy’s Teaching Award from the Class of 2014. He authored and successfully discussed with members of the Texas Legislature the creation of a clinical research unit at SASH that was funded by the Texas Legislature and jointly governed by the UT Austin College of Pharmacy\, UT Health Science Center San Antonio Department of Psychiatry and SASH. Dr. Saklad initiated and developed the first websites for the UT Austin College of Pharmacy in 1994\, the College of Psychiatric and Neurologic Pharmacists (CPNP; now the American Association of Psychiatric Pharmacists\, AAPP) in 1997\, and the CPNP Foundation in 2015. He helped to design\, organize\, and was a founding member of CPNP when it incorporated in 1998 as well as the CPNP Foundation in 2012. In 2003\, he was elected to the Board of Directors of the CPNP for a two-year term. He has served as a member or officer of the CPNP Communications Committee\, was the Founding Senior Editor of the Mental Health Clinician\, CPNP’s Open Access journal\, Treasurer of the CPNP Foundation\, and a member of the CPNP Business Development Committee. He is the Director of The University of Texas Psychiatric Pharmacy Program\n \n \n\n\n \n \n \n \n Dennis Pabis\, PharmD\, BCPP (OPDC)\n Senior Medical Science Liaison \n \n \n \n\n\nSpeaker Stephen R. Saklad\, PharmD\, BCPP is a paid consultant of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)Speaker Dennis Pabis\, PharmD\, BCPP is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. URL:https://psychu.org/event/pharmacokinetics-plasma-concentrations-their-clinical-relevance/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2022/11/Pharmacokinetics-Plasma-Concentrations_912x506__shutterstock_1962671197.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20230111T120000 DTEND;TZID=America/New_York:20230111T130000 DTSTAMP:20240328T044027 CREATED:20221026T142624Z LAST-MODIFIED:20230111T203728Z UID:10003894-1673438400-1673442000@psychu.org SUMMARY:Burden & Treatment Considerations For Agitation Associated With Alzheimer’s Dementia DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n Agitation associated with Alzheimer’s Dementia (AAD) lead to worsening outcomes in an already devastating disease. A patient-centered focus is recommended for a comprehensive treatment plan. In this webinar\, the speakers will review the burden of AAD\, then discuss current treatment recommendations and unmet needs. \nObjectives: \n\nReview the economic and caregiver burden related to agitation associated with Alzheimer’s Disease (AAD)\nList the currently available treatment recommendations and guidelines for AAD treatment recommendations\nIdentify gaps with current treatment options\, both pharmacologic and nonpharmacologic\n \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n W. Clay Jackson\, MD\, DipTh\n Assistant Professor of Clinical Psychiatry & Family Medicine; University of TN College of Medicine \n \n \n \n\n\n \n \n \n \n Bryan Archuleta\, PharmD (OPDC)\n Senior Long-Term Care Medical Science Liaison \n \n \n \n\n\nSpeaker W. Clay Jackson\, MD\, DipTh is a paid consultant of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)Speaker Bryan Archuleta\, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. URL:https://psychu.org/event/burden-treatment-considerations-for-agitation-associated-with-alzheimers-dementia/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2022/11/Alzheimer-support_912x506_shutterstock_2128747586.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20221213T120000 DTEND;TZID=America/New_York:20221213T130000 DTSTAMP:20240328T044027 CREATED:20221014T175656Z LAST-MODIFIED:20221213T185844Z UID:10003889-1670932800-1670936400@psychu.org SUMMARY:Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment of Schizophrenia DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n Trace amines and trace amine-associated receptors (TAAR) are found throughout the brain and peripheral tissues and have modulating effects on neurotransmitters including dopamine\, glutamate\, and serotonin.1\,2 The speaker(s) will discuss what are some of the potential effects of TAAR1 on neurotransmitter signaling related to schizophrenia and some of the preclinical data\, as well as share the potential role of TAAR1 beyond schizophrenia.\n\nObjectives:\n\n Summarize the Unmet Needs of Schizophrenia as it Relates to Neural Circuitry\n Introduction to Trace Amines (TA) and Trace Amine-Associated Receptors (TAARs) and Their Potential Relationship to Schizophrenia\n Discuss Potential Modulating Effects of TAAR1 on Neurotransmitter Signaling Associated with Schizophrenia Pathophysiology\n\n \nReferences \n\n\n Dedic N\, et al. Int J Mol Sci. 2021;22(24):13185. doi:10.3390/ijms222413185\n Nair PC\, et al. Mol Psychiatry. August 10\, 2021. doi:10.1038/s41380-021-01250-7\n \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Christoph Correll\, MD\n Chair of the Department of Child and Adolescent Psychiatry\, Psychosomatic Medicine and Psychotherapy\, Charité Universitätsmedizin Berlin\, Campus Virchow\, Berlin\, Germany. Professor of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell\, New York\, USA. \n \n \n More\n \n Professor Correll’s research and clinical work focus on the identification\, characterization and treatment of youth with severe mental illness\, including psychotic and mood disorders\, spanning all disease stages from the prodrome to first and multi-episode illness and up to refractory illness.\nHe further focuses on psychopharmacology\, epidemiology\, comparative effectiveness\, meta-analyses\, the risk–benefit evaluation of psychotropic medications\, and the interface between physical health and mental health.\n \n \n\n\n \n \n \n \n Jehan Marino\, PharmD\, BCPP (OPDC)\n Medical Science Liaison \n \n \n \n\n\nSpeaker Christoph Correll\, MD is a paid consultant of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)Speaker Jehan Marino\, PharmD\, BCPP is an employee for Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. URL:https://psychu.org/event/trace-amine-associated-receptor-1-taar1-a-potential-new-target-for-the-treatment-of-schizophrenia/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2022/11/Schizophrenia-Treatment_912x506_shutterstock_1402043495.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20221206T120000 DTEND;TZID=America/New_York:20221206T130000 DTSTAMP:20240328T044027 CREATED:20221109T000307Z LAST-MODIFIED:20221206T184259Z UID:10003901-1670328000-1670331600@psychu.org SUMMARY:The Value Of Digital Therapeutics DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n Webinar\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities\n Description: Digital therapeutics\, a subset of digital health\, are evidence-based\, clinically validated software that combine health and technology to prevent\, treat\, or manage a medical condition. In this discussion\, Dr. Madhukar Trivedi and Dr. Albert Mei will introduce the role of digital therapeutics in the current mental health landscape\, describe the value that digital therapeutics may bring to patients\, providers\, payers\, and health systems\, and explore the regulation and reimbursement pathways in today’s digital health landscape. \nObjectives: \n\nIntroduce the role of digital therapeutics in the current mental health landscape (obj 1)\nDescribe the value that digital therapeutics may bring to patients\, providers\, payers\, and health systems (obj 2)\nExplore regulation and reimbursement in today’s digital health landscape (obj 3)\n \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Madhukar Trivedi\, MD\n Director\, Center For Depression Research & Clinical Care; Betty Jo Hay Distinguished Chair\, Mental Health & Julie K. Hersh Chair\, Depression Research & Clinical Care\, UT Southwestern Medical Center\n\n \n \n \n More\n \n Dr. Trivedi is a psychiatrist and the Julie K. Hersh Chair in Depression Research and Clinical Care at UT Southwestern Medical Center in Dallas\, TX. Dr. Trivedi completed his medical studies at Baroda Medical College in Baroda\, India\, and he completed his residency in Psychiatry at University General Hospital Medical College in Baroda\, India\, and Henry Ford Hospital in Detroit\, Michigan. Dr. Trivedi is board certified by the American Board of Psychiatry and Neurology.\n \n \n\n\n \n \n \n \n Albert Mei\, PharmD\n National Lead for Digital Innovation and Managed Ambulatory Care\, Elevance Caremore \n \n \n More\n \n Albert Mei\, PharmD\, leads Digital Innovation and Managed Ambulatory Care at Elevance Caremore. Past managed care experiences include Sales and Account Management at Express Scripts/Evernorth\, managed care residency with Navitus Health Solutions\, and Quality and Patient Engagement at Aetna Medicare. His professional experience combined with Elevance’s vertical integration business model provides him with a 360-degree view on the healthcare payer landscape. He maintains a formulary philosophy that focuses on total cost of care and transparency to access. Additionally\, he serves as an independent consultant to pharmaceutical manufacturers to help teams better engage customers and understand the underlying thoughts driving payer pharmacy teams.\n \n \n\n\n \n \n \n \n Anna Basoff\, PharmD (OPDC)\n Managed Market Liaison \n \n \n More\n \n \n\nAnna Basoff\, PharmD\, is a Managed Market Liaison for Otsuka covering the US Northeast region. Dr. Basoff gained her Doctor of Pharmacy (PharmD) from Rutgers University. After graduating\, she joined Horizon Blue Cross & Blue Shield of NJ as a clinical pharmacist where she worked on initiatives that included MTM (medication therapy management)\, digital health\, and adherence. In the past\, she has also worked as a pharmacist for Walgreens. She resides in NJ and continues to work with the Rutgers pharmacy students\, as diplomat to their Academy of Managed Care Pharmacy (AMCP) student chapter.\n\n\n \n \n\n\nSpeaker Dr. Madhukar Trivedi is a paid consultant of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)Speaker Dr. Albert Mei was not compensated for their participation.Speaker Anna Basoff\, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What World Bipolar Day Means To Me Featuring Dr. Saklad\n \n Interview March 27\, 2024\n \n Please join us as Dr. Stephen Saklad shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Goldberg\n \n Interview March 26\, 2024\n \n Please join us as Dr. Joseph Goldberg shares his thoughts and perspectives on what bipolar day means to him. \n \n \n What World Bipolar Day Means To Me Featuring Dr. Tohen\n \n Interview March 25\, 2024\n \n Please join us as Dr. Mauricio Tohen shares his thoughts and perspectives on what bipolar day means to him. URL:https://psychu.org/event/the-value-of-digital-therapeutics/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2022/11/mental-health-digital-therapy_912x506_shutterstock_197310038.jpg END:VEVENT END:VCALENDAR